Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-839
Closed -$209K 200
2021
Q1
$209K Buy
+839
New +$200K 0.05% 191
2020
Q3
$260K Sell
1,023
-58
-5% -$14.4K 0.07% 159
2020
Q2
$255K Sell
1,081
-40
-4% -$9.13K 0.08% 153
2020
Q1
$227K Sell
1,121
-47
-4% -$10.3K 0.08% 147
2019
Q4
$282K Sell
1,168
-60
-5% -$13.2K 0.09% 158
2019
Q3
$238K Sell
1,228
-197
-14% -$37.8K 0.08% 162
2019
Q2
$263K Sell
1,425
-62
-4% -$11.1K 0.09% 155
2019
Q1
$283K Sell
1,487
-34
-2% -$6.49K 0.1% 143
2018
Q4
$296K Buy
1,521
+12
+0.8% +$2.34K 0.11% 139
2018
Q3
$313K Sell
1,509
-116
-7% -$22.9K 0.1% 135
2018
Q2
$300K Sell
1,625
-20
-1% -$3.54K 0.11% 132
2018
Q1
$280K Sell
1,645
-82
-5% -$15.1K 0.1% 135
2017
Q4
$300K Buy
1,727
+175
+11% +$31K 0.1% 129
2017
Q3
$289K Buy
1,552
+111
+8% +$19.7K 0.11% 118
2017
Q2
$248K Buy
1,441
+77
+6% +$12.5K 0.09% 127
2017
Q1
$224K Buy
+1,364
New +$227K 0.09% 132

Other funds holding AMGN

Probity Advisors's AMGN Position: Q2 2021 in Review

Probity Advisors sold out of Amgen (AMGN) in Q2 2021, closing a stake of 839 shares — an estimated $209K sold.

Probity Advisors first reported a position in AMGN in Q1 2017 and held it in 16 quarters. The position peaked at $313K in Q3 2018. 2,194 funds tracked by Wall St. Rank hold AMGN as of Q2 2021.

  • Probity Advisors reported no remaining Amgen position as of Q2 2021 after selling out during the quarter.
  • Probity Advisors sold 839 Amgen shares in Q2 2021, an estimated $209K.
  • Probity Advisors first reported a position in Amgen in Q1 2017 and held it in 16 quarters.
  • Probity Advisors's Amgen position peaked at $313K in Q3 2018.
  • 2,194 funds tracked by Wall St. Rank held Amgen as of Q2 2021.

Based on Probity Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.